Gad Berdugo, MSc. Eng., MBA
Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a strategic and financial advisory firm focusing on the global biotechnology sector. He currently serves as Vice Chairman of the Board of Directors of clinical development stage precision oncology company, Diaccurate. Mr. Berdugo brings over 35 years of biotech corporate & business development, strategy, operational, financial, investment and general venture management experience. He served as CBO at CRISPR gene editing pioneer Editas (Nasdaq EDIT); Co-founder and CEO at personalized neoantigen cancer vaccine venture, EpiVax Oncology Inc.; CFO and EVP at Immune Pharmaceuticals Inc. (Nasdaq IMNP); Managing Director and Head of Life Sciences at Tegris Advisors, a strategic and financial advisory boutique; Founder and Managing Partner of the Explorium Global Life Sciences Investment Fund; Director, Senior Equity Research Analyst and Life Sciences Sector Leader at Lazard, Asset Management Group. Prior to that, he served as a Director of Global Business Development within Baxter’s Biopharmaceuticals group and started his career at Abbott Labs. Mr. Berdugo received his B.Sc. with Honors in Biotechnology from Imperial College London, his M.Sc. in Biochemical Engineering from University College London and his M.B.A. from H.E.C. Paris. He serves on the Board of Directors of Friends of H.E.C. Inc. and Friends of U.C.L. Inc. Mr. Berdugo is bilingual in French and English and has dual US and French citizenships. He resides with his wife in New York City.